James Cunningham

Dr. James Cunningham


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HLHu Liu
Hu Liu
YTYe Tian
Ye Tian
KLKyungae Lee
Kyungae Lee
PKPranav Krishnan
Pranav Krishnan
MWMay Kwang-Mei Wang
May Kwang-Mei Wang
JCJames Cunningham
James Cunningham

28 September 2018 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
MWMay Kwang-Mei Wang
May Kwang-Mei Wang
TRTao Ren
Tao Ren
HLHu Liu
Hu Liu
SLSun-Young Lim
Sun-Young Lim
KLKyungae Lee
Kyungae Lee
JCJames Cunningham
James Cunningham
Lassa fever virus (LASV) is endemic in West Africa and causes severe hemorrhagic fever and sensorineural hearing loss. We identified a small molecule inhibitor of LASV and used it to analyze the mechanism of entry. Using a photo-reactive analog that retains antiviral activity as a probe, we identified the inhibitor target as lysosome-associated membrane protein 1 (LAMP1), a host factor that binds to the LASV glycoprotein (GP) during infection. We found that LAMP1 binding to LASV GP is cholesterol-dependent, and that the inhibitor blocks infection by competing with cholesterol in LAMP1. Mutational analysis of a docking-based model identified a putative inhibitor binding site in the cholesterol-binding pocket within the LAMP1 domain that binds GP. These findings identify a critical role for cholesterol in LASV entry and a potential target for therapeutic intervention. Lassa fever virus (LASV) is endemic in West Africa and can cause fatal infection. Currently, there is no vaccine or effective post-exposure treatment. Here we identify 3.3, a small molecule that inhibits LASV infection by targeting lysosome-associated membrane protein 1 (LAMP1), which binds to the LASV glycoprotein (GP) and promotes virus membrane fusion and infection. Our analysis reveals that cholesterol is an important cofactor for LAMP1 binding to LASV GP and that 3.3 inhibits infection by displacing cholesterol from LAMP1. Thus, 3.3 is a candidate for further development as a LASV inhibitor.

1 February 2001 in Parasitology
Verified
Journal Article
Closed access
PDF file
ZBZ.A. Bascal
Z.A. Bascal
JCJames Cunningham
James Cunningham
Lindy Holden-DyeLindy Holden-Dye
Lindy Holden-Dye
MOM. O'SHea
M. O'SHea
RWRobert Walker
Robert Walker
In this paper we report on the biochemical presence of nitric oxide synthase (NOS)-like activity in Ascaris suum tissue and examine the pharmacological effect of NO donors on A. suum muscle strip preparation. NOS activity was determined by monitoring the formation of [3H]citrulline from [3H]L-arginine and NO formation via the oxyhaemoglobin assay. Neuromuscular tissue from A. suum which stained positively for NADPH diaphorase, contained NOS activity. Neither NOS activity nor NADPH diaphorase staining was detected in intestinal tissue. The absence of Ca2+, NADPH and other co-factors normally required for mammalian neuronal NOS activity only partially reduced the formation of both citrulline and NO by A. suum neuromuscular homogenate. The results of the biochemical assays indicate the presence of an enzyme capable of producing NO and citrulline, but with a different profile from that of rat neuronal NOS. We also present preliminary evidence for the action of NO (NO donors) in the neuromuscular system of A. suum.


25 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
SSSindhu Carmen Sivakumaren
Sindhu Carmen Sivakumaren
HSHyeseok Shim
Hyeseok Shim
TZTinghu Zhang
Tinghu Zhang
FFFleur M. Ferguson
Fleur M. Ferguson
MLMark R. Lundquist
Mark R. Lundquist
NGNathanael S. Gray
Nathanael S. Gray
Summary: The PI5P4Ks have been demonstrated to be important for cancer cell proliferation and other diseases. However, the therapeutic potential of targeting these kinases is understudied due to a lack of potent, specific small molecules available. Here we present the discovery and characterization of a novel pan-PI5P4K inhibitor, THZ-P1-2, that covalently targets cysteines on a disordered loop in PI5P4Kα/β/γ. THZ-P1-2 demonstrates cellular on-target engagement with limited off-targets across the kinome. AML/ALL cell lines were sensitive to THZ-P1-2, consistent with PI5P4K’s reported role in leukemogenesis. THZ-P1-2 causes autophagosome clearance defects and upregulation in TFEB nuclear localization and target genes, disrupting autophagy in a covalent-dependent manner and phenocopying the effects of PI5P4K genetic deletion. Our studies demonstrate that PI5P4Ks are tractable targets, with THZ-P1-2 as a useful tool to further interrogate the therapeutic potential of PI5P4K inhibition and inform drug discovery campaigns for these lipid kinases in cancer metabolism and other autophagy-dependent disorders.